No profile data available.
Ultragenyx Pharmaceutical Inc. (RARE) is a healthcare company in the blood disorder treatment drugs industry, based in Novato, United States, with about 1,371 full-time employees.
It reported revenue of $673.00 million for fiscal year 2025, up 20.1% from fiscal year 2024, and net income of -$575.00 million. North America was its largest region in fiscal year 2025, with 56% of revenue. Its market capitalization was $1.53 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Ultragenyx Pharmaceutical reported $673.00 million in revenue for fiscal year 2025, up 20.1% from $560.23 million in fiscal year 2024.
North America: 56% of revenue by region in fiscal year 2025, followed by Latin America (25%).
$1.53 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Protagonist Therapeutics, Inc. (PTGX), Agios Pharmaceuticals, Inc. (AGIO), uniQure N.v. (QURE), Ardelyx, Inc. (ARDX).